TXG
Bearish signalScored 2026-09-28 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
10x Genomics, Inc.
- Nom
- 10x Genomics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $9.3B
- Employés
- 1,178
- PDG
- Serge Saxonov
- Site web
- https://www.10xgenomics.com
- Marché
- ABIOGNNSFILMNLABQGEN
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 103 330 titres (~6 887 590,52 $ US)
- Insiders
- SULIMAN SHEHNAAZSaxonov SergeSTUELPNAGEL JOHN RHindson Benjamin J.Teichmann Sarah A.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,482,333
Avg sell (VWAP, 90d window) $63.62 vs last close $93.50 (+47.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,798,137 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-22
- Liquidity
- Liquid $292,368,525/day · 20d vol
- Last synced
-
2026-10-02 21:11:03
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-22 | SULIMAN SHEHNAAZ | Sell · S · 10b5-1 | 1,222 | $82.28 | $100,542 | Form 4 |
| 2026-09-22 | Saxonov Serge | Sell · S · 10b5-1 | 2,800 | $82.36 | $230,622 | Form 4 |
| 2026-09-09 | Taich Adam | Sell · S · 10b5-1 | 13,754 | $65.26 | $897,550 | Form 4 |
| 2026-09-03 | STUELPNAGEL JOHN R | Sell · S | 6,174 | $62.61 | $386,533 | Form 4 |
| 2026-08-26 | Saxonov Serge | Sell · S · 10b5-1 | 492 | $64.75 | $31,855 | Form 4 |
| 2026-08-24 | Hindson Benjamin J. | Sell · S | 13,818 | $63.02 | $870,860 | Form 4 |
| 2026-08-24 | SULIMAN SHEHNAAZ | Sell · S · 10b5-1 | 1,646 | $63.97 | $105,289 | Form 4 |
| 2026-08-24 | Saxonov Serge | Sell · S | 18,545 | $63.02 | $1,168,775 | Form 4 |
| 2026-08-24 | Taich Adam | Sell · S | 17,166 | $63.02 | $1,081,853 | Form 4 |
| 2026-08-14 | Teichmann Sarah A. | Sell · S · 10b5-1 | 2,273 | $57.15 | $129,902 | Form 4 |
| 2026-08-13 | Teichmann Sarah A. | Sell · S · 10b5-1 | 5,278 | $57.29 | $302,377 | Form 4 |
| 2026-08-11 | STUELPNAGEL JOHN R | Sell · S | 3,000 | $58.73 | $176,175 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-28 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
TXG demonstrates genuine operational improvement with strong liquidity (score 85) and recovering margins, but the near-total absence of a positive catalyst (score 15) and coordinated insider selling of $6.89M by top…
The first sentence of the analysis written for TXG on 2026-09-28 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 4.46 · operating margin -17% — readings disagree
Suggested stop 71.64, nearest stored support minus 0.5 ATR(23.4% under the last close). Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | |
| Ebit Margin | -6.2% | -29.1% | -40.2% | -31.3% | -10.8% | |
| Ebitda Margin | 0.6% | -21.9% | -33.2% | -24.9% | -5.0% | |
| Operating Profit Margin | -17.2% | -31.9% | -42.9% | -32.5% | -10.8% | |
| Pretax Profit Margin | -6.2% | -29.1% | -40.2% | -31.4% | -11.0% | |
| Continuous Operations Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | |
| Net Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | |
| Bottom Line Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | |
| Current Ratio | 4.460 | 4.968 | 4.687 | 4.849 | 6.774 | |
| Quick Ratio | 4.093 | 4.261 | 4.107 | 4.226 | 6.231 | |
| Solvency Ratio | 0.001 | -0.666 | -0.944 | -0.596 | -0.149 | |
| Cash Ratio | 3.089 | 2.925 | 2.825 | 1.678 | 5.323 | |
| Price To Earnings Ratio | -46.600 | -9.447 | -25.670 | -24.959 | -281.057 | |
| Price To Earnings Growth Ratio | 0.605 | 0.312 | -0.521 | -0.142 | 3.118 | |
| Forward Price To Earnings Growth Ratio | 0.605 | 0.312 | -0.521 | -0.142 | 3.118 | |
| Price To Earnings Diluted Ratio | -46.600 | -9.447 | -25.670 | -24.959 | -281.057 | |
| Price To Earnings Diluted Growth Ratio | 0.605 | 0.312 | -0.521 | -0.142 | 3.118 | |
| Price To Book Ratio | 2.555 | 2.436 | 8.848 | 5.149 | 20.105 | |
| Price To Sales Ratio | 3.165 | 2.832 | 10.597 | 8.034 | 33.512 | |
| Price To Free Cash Flow Ratio | 15.637 | -301.917 | -101.305 | -25.105 | -134.018 | |
| Price To Operating Cash Flow Ratio | 14.955 | 259.556 | -431.437 | -123.460 | -769.074 | |
| Debt To Assets Ratio | 0.151 | 0.090 | 0.099 | 0.092 | 0.080 | |
| Debt To Equity Ratio | 0.198 | 0.116 | 0.129 | 0.118 | 0.100 | |
| Debt To Capital Ratio | 0.165 | 0.104 | 0.114 | 0.106 | 0.091 | |
| Long Term Debt To Capital Ratio | 0.084 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.308 | 1.294 | 1.302 | 1.277 | 1.246 | |
| Working Capital Turnover Ratio | 1.289 | 1.306 | 1.272 | 0.905 | 0.758 | |
| Operating Cash Flow Ratio | 0.887 | 0.057 | -0.120 | -0.257 | -0.194 | |
| Operating Cash Flow Sales Ratio | 0.212 | 0.011 | -0.025 | -0.065 | -0.044 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | -0.860 | 4.259 | 4.918 | 5.739 | |
| Debt Service Coverage Ratio | 0.025 | -34,728.750 | -6,407.485 | -278.399 | -33.606 | |
| Interest Coverage Ratio | 0.000 | -48,639.750 | -8,040.273 | -352.824 | -61.100 | |
| Short Term Operating Cash Flow Coverage Ratio | 12.385 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.863 | 0.081 | -0.159 | -0.353 | -0.261 | |
| Capital Expenditure Coverage Ratio | 22.923 | 0.538 | -0.307 | -0.255 | -0.211 | |
| Dividend Paid And Capex Coverage Ratio | 22.923 | 0.538 | -0.307 | -0.255 | -0.211 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 439.612 | -10.958 | -30.679 | -31.321 | -647.772 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.0% | ▲1.2% | ▼-3.9% |
| Ebit Margin | -6.2% | ▲22.9% | ▲17.3% |
| Ebitda Margin | 0.6% | ▲22.6% | ▲17.5% |
| Operating Profit Margin | -17.2% | ▲14.6% | ▲9.8% |
| Pretax Profit Margin | -6.2% | ▲22.9% | ▲17.4% |
| Continuous Operations Profit Margin | -6.8% | ▲23.1% | ▲17.6% |
| Net Profit Margin | -6.8% | ▲23.1% | ▲17.6% |
| Bottom Line Profit Margin | -6.8% | ▲23.1% | ▲17.6% |
| Current Ratio | 4.460 | ▼-0.508 | ▼-0.688 |
| Quick Ratio | 4.093 | ▼-0.168 | ▼-0.491 |
| Solvency Ratio | 0.001 | ▲0.667 | ▲0.472 |
| Cash Ratio | 3.089 | ▲0.164 | ▼-0.079 |
| Price To Earnings Ratio | -46.600 | ▼-37.153 | ▲30.947 |
| Price To Earnings Growth Ratio | 0.605 | ▲0.293 | ▼-0.069 |
| Forward Price To Earnings Growth Ratio | 0.605 | ▲0.293 | ▼-0.069 |
| Price To Earnings Diluted Ratio | -46.600 | ▼-37.153 | ▲30.947 |
| Price To Earnings Diluted Growth Ratio | 0.605 | ▲0.293 | ▼-0.069 |
| Price To Book Ratio | 2.555 | ▲0.119 | ▼-5.263 |
| Price To Sales Ratio | 3.165 | ▲0.333 | ▼-8.463 |
| Price To Free Cash Flow Ratio | 15.637 | ▲317.555 | ▲124.979 |
| Price To Operating Cash Flow Ratio | 14.955 | ▼-244.601 | ▲224.847 |
| Debt To Assets Ratio | 0.151 | ▲0.061 | ▲0.049 |
| Debt To Equity Ratio | 0.198 | ▲0.082 | ▲0.066 |
| Debt To Capital Ratio | 0.165 | ▲0.061 | ▲0.049 |
| Long Term Debt To Capital Ratio | 0.084 | ▲0.084 | ▲0.068 |
| Financial Leverage Ratio | 1.308 | ▲0.014 | ▲0.022 |
| Working Capital Turnover Ratio | 1.288 | ▼-0.017 | ▲0.183 |
| Operating Cash Flow Ratio | 0.887 | ▲0.830 | ▲0.812 |
| Operating Cash Flow Sales Ratio | 0.212 | ▲0.201 | ▲0.194 |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | ▲1.816 | ▼-2.046 |
| Debt Service Coverage Ratio | 0.025 | ▲34728.775 | ▲8289.668 |
| Interest Coverage Ratio | 0.000 | ▲48639.750 | ▲11418.789 |
| Short Term Operating Cash Flow Coverage Ratio | 12.385 | ▲12.385 | ▲9.908 |
| Operating Cash Flow Coverage Ratio | 0.863 | ▲0.782 | ▲0.829 |
| Capital Expenditure Coverage Ratio | 22.923 | ▲22.386 | ▲18.386 |
| Dividend Paid And Capex Coverage Ratio | 22.923 | ▲22.386 | ▲18.386 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 439.612 | ▲450.570 | ▲495.835 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.03B | $1.73B | $6.56B | $4.15B | $16.44B | |
| Enterprise value | $1.72B | $1.47B | $6.29B | $4.02B | $15.93B | |
| EV / Sales | 2.67x | 2.40x | 10.17x | 7.79x | 32.48x | |
| EV / Op. cash flow | 12.63x | 220.32x | -414.07x | -119.75x | -745.42x | |
| EV / Free cash flow | 13.21x | -256.28x | -97.23x | -24.35x | -129.90x | |
| EV / EBITDA | 439.61x | -10.96x | -30.68x | -31.32x | -647.77x | |
| Net debt / EBITDA | -80.90x | 1.95x | 1.29x | 0.97x | 20.55x | |
| Current ratio | 4.46x | 4.97x | 4.69x | 4.85x | 6.77x | |
| Income quality | -3.12x | -0.04x | 0.06x | 0.20x | 0.37x | |
| Graham net-net | $3 | $2 | $2 | $3 | $4 | |
| Tax burden | 109.1% | 102.8% | 102.5% | 102.5% | 108.4% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.3% | 101.6% | |
| Working capital | $531.0M | $466.8M | $468.9M | $504.1M | $637.2M | |
| Invested capital | $885.0M | $796.9M | $834.9M | $890.7M | $897.6M | |
| Return on assets | -4.2% | -19.9% | -26.4% | -16.1% | -5.7% | |
| Operating ROA | -11.3% | -20.7% | -26.6% | -16.4% | -5.4% | |
| Return on tangible assets | -4.5% | -20.3% | -27.0% | -16.6% | -5.9% | |
| Return on equity | -5.5% | -25.7% | -34.4% | -20.6% | -7.1% | |
| Return on invested capital | -12.3% | -24.0% | -31.2% | -18.5% | -5.8% | |
| Return on capital employed | -12.5% | -24.3% | -31.7% | -18.7% | -5.8% | |
| Earnings yield | -2.1% | -10.6% | -3.9% | -4.0% | -0.4% | |
| Free cash flow yield | 6.4% | -0.3% | -1.0% | -4.0% | -0.7% | |
| Capex / Op. cash flow | 4.4% | 186.0% | -325.9% | -391.8% | -473.9% | |
| Capex / Depreciation | 13.5% | 28.4% | 113.5% | 398.9% | 358.5% | |
| Capex / Sales | 0.9% | 2.0% | 8.0% | 25.5% | 20.6% | |
| SG&A / Sales | 49.2% | 56.4% | 55.5% | 57.8% | 52.5% | |
| R&D / Sales | 37.1% | 43.3% | 43.7% | 51.4% | 43.2% | |
| Stock comp / Sales | 17.0% | 23.0% | 27.0% | 26.5% | 19.6% | |
| Intangibles / Total assets | 6.4% | 2.2% | 2.2% | 2.7% | 2.9% | |
| Days sales outstanding | 47d | 53d | 68d | 74d | 63d | |
| Days payables outstanding | 23d | 24d | 27d | 65d | 85d | |
| Operating cycle | 150d | 207d | 196d | 321d | 359d | |
| Cash conversion cycle | 127d | 183d | 169d | 256d | 273d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-26 10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 Shares 10x Genomics (NASDAQ: TXG - Get Free Report) Director Shehnaaz Suliman sold 5,723 shares of the business''s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total transaction of $464,650.37. Following the transaction, the director directly owned 23,792 shares of the company''s stock, valued at
- 2026-09-26 10x Genomics (NASDAQ:TXG) Stock: Insider Serge Saxonov Sells 25,000 Shares 10x Genomics (NASDAQ: TXG - Get Free Report) CEO Serge Saxonov sold 25,000 shares of 10x Genomics stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total value of $2,030,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,050,249
- 2026-09-22 3 Analysts, 3 Trades to Make Today Louis says buy the AI dip
- 2026-09-21 10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors On September 21, 2026, 10x Genomics Inc (TXG) shares rose 3.3% to a current price of $79.10. The stock has seen a remarkable performance over the past year, wit
- 2026-09-21 Analyzing MindWalk (NASDAQ:HYFT) & 10x Genomics (NASDAQ:TXG) 10x Genomics (NASDAQ: TXG - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations. Profitability This table compares 10x Genomics and MindWalk''s net
- 2026-09-17 HB Wealth Management LLC Invests $285,000 in 10x Genomics $TXG HB Wealth Management LLC purchased a new stake in 10x Genomics (NASDAQ: TXG) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 7,444 shares of the company''s stock, valued at approximately $285,000. Other institutional investors have also recently modified their holdings of the company.
- 2026-09-10 Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research 10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit''s AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit''s AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.
- 2026-09-08 10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100 On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the p
- 2026-09-03 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? TXG''s 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
- 2026-09-01 Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc''s (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.